DPP-4 Inhibitor–Metformin Combination for Glycemic Control in CKD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidiabetic therapies for type 2 diabetes, particularly in patients with chronic kidney disease (CKD), face challenges in maintaining long-term glycemic control, are associated with adverse effects, and fail to effectively prevent or treat microvascular and macrovascular complications, leading to high morbidity and mortality.
Innovation Solution
Combining a DPP-4 inhibitor, such as linagliptin, with metformin hydrochloride for treating CKD patients, particularly those with eGFR levels between 30 and 60 mL/minute/1.73 m², to improve glycemic control and prevent or delay the progression of diabetic complications like nephropathy, albuminuria, and cardiovascular events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional antidiabetic monotherapy is used, then treatment simplicity is maintained, but glycemic control efficacy deteriorates over long-term
Solution Approach 1:
The patent combines metformin (biguanide) with a DPP-4 inhibitor in a single pharmaceutical composition, allowing the drug to provide both insulin sensitizing effects and glucose-dependent insulinotropic effects. This merged approach maintains treatment simplicity while achieving superior and sustained glycemic control compared to monotherapy.
Solution Approach 2:
The invention uses a composite pharmaceutical formulation containing two distinct active ingredients (metformin and DPP-4 inhibitor) with complementary mechanisms of action. This composite approach allows the medication to address multiple pathophysiological aspects of type 2 diabetes simultaneously, improving long-term glycemic control reliability.
2Reliability
If multiple antidiabetic drugs are combined, then glycemic control efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent merges two antidiabetic agents (metformin and DPP-4 inhibitor) into a single fixed-dose combination pill, eliminating the need for patients to take multiple separate medications. This approach maintains the glycemic control benefits of combination therapy while simplifying the treatment regimen to once-daily administration.
Solution Approach 2:
The combined pharmaceutical composition serves multiple therapeutic functions simultaneously: it provides insulin sensitization (metformin), glucose-dependent insulin secretion stimulation (DPP-4 inhibitor), and addresses both fasting and postprandial hyperglycemia, making it a universal solution for comprehensive glycemic control.
3Reliability
If intensive glycemic control therapy is applied, then complication prevention is improved, but adverse effects increase
Solution Approach 1:
The DPP-4 inhibitor component provides glucose-dependent insulinotropic activity, meaning its effect is modulated by blood glucose levels. When glucose is high, the drug enhances insulin secretion; when glucose is normal or low, the effect diminishes. This parameter-based regulation allows intensive glycemic control while automatically reducing the risk of hypoglycemia-related adverse effects.
Solution Approach 2:
The combination leverages the glucose-dependent mechanism of DPP-4 inhibition to convert what could be a harmful effect (excessive insulin secretion leading to hypoglycemia) into a beneficial safety feature. The drug's effect automatically adjusts to physiological needs, providing intensive control when needed while preventing harmful hypoglycemic episodes.
4Reliability
If metformin dose is increased, then glycemic control is improved, but gastrointestinal side effects worsen
Solution Approach 1:
The DPP-4 inhibitor acts as an intermediary mechanism that enhances glucose control through a different pathway (glucose-dependent insulin secretion) rather than primarily through metformin's mechanism (hepatic glucose production inhibition). This allows achievement of glycemic control targets with lower metformin doses, thereby reducing metformin-associated gastrointestinal side effects.
Solution Approach 2:
By introducing a second mechanism of action (DPP-4 inhibition), the treatment achieves glycemic control through parameter changes in insulin secretion dynamics rather than relying solely on increasing metformin dose. This alternative pathway reduces the need for high metformin doses and their associated gastrointestinal adverse effects.
Data Source
AI summary
The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.